进展期食管鳞癌新辅助放化疗与新辅助化疗的<i>Meta分析</i>

doi:10.3760/cma.j.cn113030-20191112-00470

摘要
图/表
参考文献
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的系统评价新辅助放化疗(NCRT)联合手术与新辅助化疗(NCT)联合手术治疗进展期食管鳞癌的疗效和安全性。方法利用计算机检索PubMed、The Cochrane Library、EMbase、CBM、CNKI、WanFang、VIP数据库,搜集NCRT与NCT联合手术治疗食管鳞癌的临床对照研究,检索时限均从建库至2019年1月。由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.3软件进行Meta分析。结果共纳入8项临床对照研究,包括食管鳞癌患者995例。Meta分析结果显示NCRT对比NCT组,经手术治疗后无肿瘤细胞残存(R0)切除率更高(OR=2.14,95%CI为1.03~4.45,P=0.040)、病理完全缓解率(pCR)更高(OR=4.19,95%CI为1.71~10.28,P=0.002);两组术后并发症发生率(OR=1.37,95%CI为0.76~2.48,P=0.300)和围术期死亡风险(OR=1.28,95%CI为0.58~2.83,P=0.540)相近;NCRT组的食管鳞癌患者的远期生存情况更好(HR=0.77,95%CI为0.64~0.92,P=0.005)。结论 NCRT联合手术对比NCT联合手术治疗进展期食管鳞癌能够有更高的R0切除率、pCR率,并不会明显增加围术期并发症发生和围术期死亡风险,且能够更加明显的改善食管鳞癌患者的远期生存。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	程良
	高薇
	田东
	杨毫
	冉兴强
	施贵冬
	皈燕
	付茂勇

关键词 ：食管肿瘤/新辅助放化疗法, 食管肿瘤/新辅助化疗, 荟萃分析

Abstract：Objective To systematically evaluate the efficacy and safety of neoadjuvant chemoradiotherapy (NCRT) plus surgery versus neoadjuvant chemotherapy (NCT) plus surgery in the treatment of advanced esophageal squamous cell carcinoma. Methods Clinical controlled trials of comparing the treatment of NCRT plus surgery with NCT plus surgery for esophageal squamous cell carcinoma were electronically searched from the databases including PubMed, The Cochrane Library, EMbase, CBM, CNKI, WanFang and VIP from the inception of databases to January, 2019. Two reviewers independently screened the literatures, extracted data and assessed the risk of bias of the included studies. And then, a meta-analysis was performed by using RevMan 5.3 software. Results A total of 8 clinical control studies were included, including 995 patients with esophageal squamous cell carcinoma. Meta-analysis Results showed that compared with the NCT group, the R0 resection rate was significantly higher(OR=2.14, 95%CI:1.03-4.45, P=0.040)and the pathological complete response (pCR) rate was significantly higher(OR=4.19, 95%CI:1.71-10.28, P=0.002)in the NCRT group. The incidence of postoperative complications (OR=1.37, 95%CI:0.76-2.48, P=0.300) and the risk of perioperative death (OR=1.28, 95%CI:0.58-2.83, P=0.54) were not significantly different between two groups. The long-term survival of patients with esophageal squamous cell carcinoma in the NCRT group was significantly better compared with that in the NCT group (HR=0.77, 95%CI:0.64-0.92, P=0.005). Conclusions Compared with NCT plus surgery for advanced esophageal squamous cell carcinoma, NCRT plus surgery has higher R0 resection rate and pCR rate,does not significantly increase the risk of perioperative complications or perioperative death, and significantly improves the long-term survival of esophageal squamous cell carcinoma patients.

Key words： Esophageal neoplasm/neoadjuvant chemoradiotherapy Esophageal neoplasm/neoadjuvant chemotherapy Meta-analysis

收稿日期: 2019-11-12

通讯作者: 付茂勇,Email:fumaoyongmd@163.com

引用本文:

程良,高薇,田东等. 进展期食管鳞癌新辅助放化疗与新辅助化疗的Meta分析[J]. 中华放射肿瘤学杂志, 2021, 30(1): 34-41.

Cheng Liang,Gao Wei,Tian Dong et al. Meta-analysis of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for advanced esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(1): 34-41.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20191112-00470 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2021/V30/I1/34

[1] 左婷婷,郑荣寿,曾红梅,等. 中国食管癌发病状况与趋势分析[J]. 中华肿瘤杂志, 2016, 38(9):703-708. DOI:10.3760/cma.j.issn.0253-3766.2016.09.013.
Zuo TT, Zheng RS, Zeng HM, et al. Incidence and trend analysis of esophageal cancer in China[J]. Chin J Oncol, 2016, 38(9):703-708. DOI:10.3760/cma.j.issn.0253-3766.2016.09.013.
[2] Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)[J]. Ann Surg Oncol, 2012, 19(1):68-74. DOI:10.1245/s10434-011-2049-9.
[3] Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer[J]. J Clin Oncol, 2009, 27(30):5062-5067. DOI:10.1200/jco.2009.22.2083.
[4] Van Hagen P, Hulshof MC, Van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22):2074-2084. DOI:10.1056/NEJMoa1112088.
[5] Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society:part 1[J]. Esophagus, 2019, 16(1):1-24. DOI:10.1007/s10388-018-0641-9.
[6] Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer[J]. Surg Today, 2019, 50(1):12-20. DOI:10.1007/s00595-019-01878-7.
[7] Sanford NN, Catalano PJ, Enzinger PC, et al. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer[J]. Dis Esophagus, 2017, 30(7):1-8. DOI:10.1093/dote/dox025.
[8] 周国志,吴清泉. 术前同步放化疗在食管癌综合治疗中的作用[J]. 世界华人消化杂志, 2012, 20(17):1526-1530. DOI:10.11569/wcjd.v20.i17.1526.
Zhou GZ, Wu QQ. Role of preoperative chemoradiotherapy in the comprehensive treatment of esophageal cancer[J]. World Chin J Dig, 2012, 20(17):1526-1530. DOI:10.11569/wcjd.v20.i17.1526.
[9] Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma:a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer[J]. World J Surg, 1992, 16(6):1104-1110. DOI:10.1007/BF02067069.
[10] Cao XF, He XT, Ji L, et al. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma[J]. Dis Esophagus, 2009, 22(6):477-481. DOI:10.1111/j.1442-2050.2008.00910.x.
[11] Von Dobeln GA, Klevebro F, Jacobsen AB, et al. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction:long-term results of a randomized clinical trial[J]. Dis Esophagus, 2018, 32(2). DOI:10.1093/dote/doy078.
[12] Klevebro F, Lindblad M, Johansson J, et al. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry[J]. Br J Surg, 2016, 103(13):1864-1873. DOI:10.1002/bjs.10304.
[13] 李雪,郝大选,杨原源,等. 局部进展期食管鳞癌新辅助放化疗与新辅助化疗比较[J]. 中华放射肿瘤学杂志, 2017, 26(3):274-278. DOI:10.3760/cma.j.issn.1004?4221.2017.03.006.
Li X, Hao DX, Yang YY, et al. Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in treating locally advanced esophageal squamous cell carcinoma[J]. Chin J Radiat Oncol, 2017, 26(3):274-278. DOI:10.3760/cma.j.issn.1004?4221.2017.03.006.
[14] 郑浩,汪灏,唐汉,等. 新辅助同步放化疗与新辅助化疗治疗局部进展期食管鳞癌的疗效分析[J]. 中华消化外科杂志, 2017,16(5):464-468. DOI:10.3760/cma.j.issn.1673-9752.2017.05.006.
Zheng H, Wang H, Tang H, et al. Effect analysis of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in the treatment of locally advanced esophageal squamous cell carcinoma[J]. Chin J Dig Surg, 2017, 16(5):464-468. DOI:10.3760/cma.j.issn.1673-9752.2017.05.006.
[15] Nakashima Y, Saeki H, Hu Q, et al. Neoadjuvant chemotherapy versus chemoradiotherapy for patients with esophageal squamous cell carcinoma[J]. Anticancer Res, 2018, 38(12):6809-6814. DOI:10.21873/anticanres.13053.
[16] Zheng Y, Liu X, Zhang R, et al. Neoadjuvant chemotherapy with or without neoadjuvant radiotherapy compared with neoadjuvant chemoradiotherapy for esophageal cancer[J]. J Thorac Dis, 2018, 10(8):4715-4723. DOI:10.21037/jtd.2018.07.124.
[17] Bharat A, Crabtree T. Management of advanced-stage operable esophageal cancer[J]. Surg Clin North Am, 2012, 92(5):1179-1197. DOI:10.1016/j.suc.2012.07.012.
[18] 曹秀峰,王山,吴必超,等. 新辅助放化疗对中晚期食管鳞癌病理分期及预后的影响[J]. 世界华人消化杂志, 2007, 15(22):2413-2417. DOI:10.3969/j.issn.1009-3079.2007.22.009.
Cao XF, Wang S, Wu BC, et al. Effects of neoadjuvant radiochemotherapy on pathological stage and prognosis of middle and advanced esophageal carcinoma[J]. World Chin J Dig, 2007, 15(22):2413-2417. DOI:10.3969/j.issn.1009-3079.2007.22.009.
[19] Klevebro F, Von Dobeln GA, Wang N, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction[J]. Ann Oncol, 2016, 27(4):660-667. DOI:10.1093/annonc/mdw010.
[20] Hao D, Li X, Yang Y, et al. Neoadjuvant chemoradiotherapy versus chemotherapy and surgery for patients with locally advanced esophageal squamous cell carcinoma[J]. Translational Cancer Research, 2017, 6(2):346-353. DOI:10.21037/tcr.2017.03.34.
[21] Tang H, Zheng H, Tan L, et al. Neoadjuvant chemoradiotherapy followed by minimally invasive esophagectomy:is it a superior approach for locally advanced resectable esophageal squamous cell carcinoma?[J]. J Thorac Dis, 2018, 10(2):963-972. DOI:10.21037/jtd.2017.12.108.
[22] Whited WM, Trivedi JR, Bond ER, et al. Optimal therapy in locally advanced esophageal cancer:a national cancer database analysis[J]. J Gastrointest Surg, 2018, 22(2):187-193. DOI:10.1007/s11605-017-3548-1.
[23] Morgan MA, Lewis WG, Crosby TD, et al. Prospective cohort comparison of neoadjuvant chemoradiotherapy versus chemotherapy in patients with oesophageal cancer[J]. Br J Surg, 2007, 94(12):1509-1514. DOI:10.1002/bjs.5671.
[24] Donahue JM, Nichols FC, Li Z, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival[J]. Ann Thorac Surg, 2009, 87(2):392-399. DOI:10.1016/j.athoracsur.2008.11.001.
[25] Stahl M, Walz MK, Riera-knorrenschild J, et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET):long-term results of a controlled randomised trial[J]. Eur J Cancer, 2017, 81:183-190. DOI:10.1016/j.ejca.2017.04.027.
[26] 郭旭峰,叶波,杨煜,等. 局部进展期食管癌新辅助治疗后微创手术可行性分析的病例对照研究[J]. 中国胸心血管外科临床杂志, 2018, 25(03):203-207. DOI:10.7507/1007-4848.201708035.
Guo XF, Ye B, Yang Y, et al. Feasibility of neoadjuvant therapy followed by minimally invasive esophagectomy for locally advanced esophageal cancer:a case control study[J]. Chin J Clin Thorac Cardiovasc Surg, 2018, 25(03):203-207. DOI:10.7507/1007-4848.201708035.
[27] Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J]. Lancet Oncol, 2011, 12(7):681-692. DOI:10.1016/s1470-2045(11)70142-5.
[28] Nakamura K, Kato K, Igaki H, et al. Three-arm phase Ⅲ trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study)[J]. Jpn J Clin Oncol, 2013, 43(7):752-755. DOI:10.1093/jjco/hyt061.
[29] Tang H, Tan L, Shen Y, et al. CMISG1701:a multicenter prospective randomized phase Ⅲ clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT3-4aN0-1M0)(NCT03001596)[J]. BMC Cancer, 2017, 17(1):450. DOI:10.1186/s12885-017-3446-7.